Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, December 18, 2014
 
Register | Sign in
Home Page > Videos > Plate Reader versus High Content RNAi Screens. Who's Right?
  Videos

Return

Plate Reader versus High Content RNAi Screens. Who's Right?
Sheffield University

There are few research areas that have expanded as quickly and spectacularly as the field of RNA interference (RNAi). RNAi based research is now maturing into a multi-billion pound industry. The notion that we can systematically switch off every gene in the genome and screen for important biological processes has become both practical and routine. Marrying this technology with High Content Microscopy we are capable of asking important phenotypic questions in a systematic way. The Sheffield RNAi Screening Facility was born from the fundamentals of the initially highly successful Drosophila melanogaster screening platform and now we operate both the Fruit Fly and Human systems. Due to the ability to compare two screens from different organisms for the first time, results will be presented from a high content siRNA screen in a Human cell line, comparing results to previously intensive screens from 3 genome-wide Drosophila screens completed using a plate reader platform. We will present the benefits and difficulties of both cellular platforms. While presenting the results, we will discuss issues such as the complexities of the type of screening approach adopted.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Cutting Out the Cellular Middleman
New technology directly reprograms skin fibroblasts for a new role.
Therapeutic Strategy May Treat a Childhood Neurological Disorder
Researchers have identified a possible therapy to treat neurofibromatosis type 1 or NF1.
Novel Agent Decreases Neuropathic Pain in Patients with Type 2 Diabetes
Promising profile of disease modification and pain reduction leads to proof of concept trials.
Anti-Diabetic Drug Springs New Hope for Tuberculosis Patients
Drug for treating diabetes can double up as adjunct treatment for tuberculosis.
People May Inherit ‘Gut’ Bacteria That Cause Crohn’s Disease And Ulcerative Colitis
Discovery is another step toward prevention and treatment of 1.6 million Americans with inflammatory bowel disease.
Long Noncoding RNAs: A Novel Prognostic Marker in Older Patients with Acute Leukemia
This study describes a new marker that might help doctors choose the least toxic, most effective treatment for older patients with acute myeloid leukemia.
Cambridge Structural Database Reaches 750,000 Entry Milestone
Essential resource to scientists around the world reaches historic record.
Scientists Gain First Glimpse of One of Nature’s Measuring ‘Rulers’
New findings offer potential to outsmart bacterial infections.
Proteins Drive Cancer Cells To Change States
When RNA-binding proteins are turned on, cancer cells get locked in a proliferative state.
Closing in on ‘Holy Grail’ of HIV Vaccine
Researchers describe a way to induce long-sought broadly neutralizing antibodies.
Scroll Up
Scroll Down
Skyscraper Banner
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn